RTKs, such as EGFR, human epidermal growth factor receptor 2 (HER2), and VEGFR, are frequently mutated or overexpressed in various kinds of cancer, leading to uncontrolled signaling and tumor growth. This evidence concerns the gene ERBB2 and neoplasm.